Press release
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry expertise.
Dr. Klaus Hinterding, Proteros CSO, stated: “We are very pleased to further deepen our existing relationship with Eisai by being selected as partner for this important program. We look forward to contributing to the success of Eisai’s research activities using our unique technology platform.
About Proteros:
Proteros is a privately held company, which provides services and proprietary technologies to support knowledge-driven drug discovery programs. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ capabilities with its unique technology platform and access to flexible resources. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Japan.
About Eisai:
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com/.
Proteros biostructures GmbH
Dr. Thomas Waldmann
Bunsenstrasse 7a
82152 Martinsried
Germany
Phone: +49 89 7007 61 – 0
E-Mail: business@proteros.com
Internet: www.proteros.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration here
News-ID: 218204 • Views: …
More Releases from Proteros biostructures GmbH
PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities
MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company.
The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception…
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas.
At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for…
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global …
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services.
Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and…
More Releases for Eisai
Migraine Drugs Market to Witness Huge Growth by 2031 - Allergen, Eisai, Ltd., As …
DataM Intelligence has published a new research report on "Migraine Drugs Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research PDF -…
Sarcoma Therapeutics Market Is Booming Worldwide | Agenus, Agios, Eisai
The "Sarcoma Therapeutics Market" intelligence report, just published by USD Analytics Market, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Sarcoma Therapeutics Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the…
Anticonvulsants Market to See Huge Growth | Pfizer, Cephalon, Eisai
Global Anticonvulsants market size, trend, and forecast to 2030 are assessed in USD Analytics Research's most recent analysis. A valuable resource document for managers, analysts, industry experts, and other key personnel, the Anticonvulsants market study includes substantial research data and proofs to help them understand market trends, growth drivers, opportunities, upcoming challenges, and competitors. The study can be easily accessed and self-analyzed.
Key Players in This Report Include:
Novartis AG (Switzerland),…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Cancer API Market Still Going Strong | Pfizer, Exelixis, Eisai, Celgene
AMA Research added a comprehensive research document of 200+ pages on 'Cancer API' market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country.
Some of the important players from a wide list of coverage used under bottom-up approach are:
Exelixis Inc. (United States)
Pfizer Inc.…
Lennox-Gastaut Syndrome (LGS) Therapeutics Pipeline to Witness Significant Growt …
According to a new research report “Lennox-Gastaut Syndrome (LGS) - Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2018” published by Pharma Proff, LGS therapeutics currently exhibits a proliferating pipeline with eight active therapeutic candidates in different stages of development.
LGS Pipeline Insights
LGS is a rare and severe form of epilepsy that mostly affects individuals during infancy or early childhood. This syndrome has the tendency to develop between the age of one…
